


Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 01-Nov-2020
 Document Type: USP Monographs
 DocId: GUID-5C8F4BBF-46C6-4822-BB7C-22D21F84A54A_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M54250_04_01
 DOI Ref: 0x0pp

© 2025 USPC
 Do not distribute

Minoxidil



$C_9H_{15}N_5O$ 209.25
 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide;
 2,4-Diamino-6-piperidinopyrimidine 3-oxide CAS RN®: 38304-91-5; UNII: 5965120SH1.

DEFINITION

Minoxidil contains NLT 97.0% and NMT 103.0% of minoxidil ($C_9H_{15}N_5O$), calculated on the dried basis.

IDENTIFICATION

Change to read:

• **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#) ▲ (CN 1-MAY-2020) : ▲ [NOTE—Methods described in 197A or 197M may be used.] ▲ (USP 1-May-2020) Do not dry specimens.

Add the following:

▲ **B.** The retention time of the minoxidil peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay. ▲
 (USP 1-May-2020)

ASSAY

Change to read:

PROCEDURE

Mobile phase: [Methanol](#), [glacial acetic acid](#), and [water](#) (70:1:30). Add 3.0 g/L of docusate sodium. Adjust with [perchloric acid](#) to a pH of 3.0.

▲ (USP 1-May-2020)

Standard solution: 0.25 mg/mL of [USP Minoxidil RS](#) in ▲ *Mobile phase* ▲ (USP 1-May-2020)

Sample solution: 0.25 mg/mL of Minoxidil in ▲ *Mobile phase* ▲ (USP 1-May-2020)

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 4-mm × 25-cm; ▲ 5-μm ▲ (USP 1-May-2020) packing [L1](#)

Flow rate: 1 mL/min

Injection volume: 10 μL

▲ **Run time:** NLT 2 times the retention time of the minoxidil peak ▲ (USP 1-May-2020)

System suitability

Sample: *Standard solution* ▲ (USP 1-May-2020)

Suitability requirements

▲ **Tailing factor:** NMT 2.0 ▲ (USP 1-May-2020)

Relative standard deviation: NMT ▲ 1.10% ▲ (USP 1-May-2020)

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of minoxidil ($C_9H_{15}N_5O$) in the portion of Minoxidil taken:

$$\text{Result} = \left(\frac{r_U}{r_S} \right) \text{▲ (USP 1-May-2020)} \times \left(\frac{C_S}{C_U} \right) \times 100$$

$r_{U\Delta}$ (USP 1-May-2020) = peak response Δ of minoxidil Δ (USP 1-May-2020) from the *Sample solution*

$r_{S\Delta}$ (USP 1-May-2020) = peak response Δ of minoxidil Δ (USP 1-May-2020) from the *Standard solution*

C_S = concentration of [USP Minoxidil RS](#) in Δ (USP 1-May-2020) the *Standard solution* (mg/mL)

C_U = concentration of Δ Minoxidil in Δ (USP 1-May-2020) the *Sample solution* (mg/mL)

Acceptance criteria: 97.0%–103.0% on the dried basis

IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.5%

Change to read:

• ORGANIC IMPURITIES

Mobile phase: Dissolve 2.0 g of sodium lauryl sulfate in a mixture of 600 mL of [methanol](#), 10 mL of [glacial acetic acid](#), and 400 mL of [water](#). Adjust with [perchloric acid](#) to a pH of 3.0 ± 0.1 .

Diluent: [Methanol](#) and [water](#) (50:50)

Standard solution: 0.005 mg/mL of [USP Minoxidil RS](#) in *Diluent*

Sensitivity solution: 0.125 µg/mL of [USP Minoxidil RS](#) in *Diluent* from the *Standard solution*

Sample solution: 0.25 mg/mL of Minoxidil in *Diluent* prepared as follows. Transfer a suitable amount of Minoxidil in an appropriate volumetric flask. Initially add *Diluent* to about 60% of the flask volume, shake on a mechanical shaker for 20 min, and then dilute with *Diluent* to volume.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 280 nm

Column: 3.9-mm × 15-cm; 4-µm packing [L1](#)

Flow rate: 0.5 mL/min

Injection volume: 40 µL

Run time: NLT 3 times the retention time of the minoxidil peak

System suitability

Samples: *Standard solution* and *Sensitivity solution*

Suitability requirements

Tailing factor: NMT 2.0, *Standard solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of the Minoxidil taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of minoxidil from the *Standard solution*

C_S = concentration of [USP Minoxidil RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Minoxidil in the *Sample solution* (mg/mL)

F = relative response factor (see *Table 1*)

Acceptance criteria: See [Table 1](#). The reporting threshold is 0.05%.

Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Pyrimidine oxide analog ^a	0.19	0.35	0.2
Pyrimidine analog ^b	0.37	0.49	0.2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Minoxidil	1.00	1.0	—
Deoxyminoxidil ^c	1.45	1.32	0.2
Any individual unspecified impurity	—	1.0	0.1
Total impurities	—	—	1.0

^a 4-Chloropyrimidine-2,6-diamine-1-oxide.

^b 6-Chloropyrimidine-2,4-diamine.

^c 6-(Piperidin-1-yl)pyrimidine-2,4-diamine.

▲ (USP 1-May-2020)

SPECIFIC TESTS

- [Loss on Drying \(731\)](#).

Analysis: Dry at 50° and at a pressure not exceeding 5 mm of mercury for 3 h.

Acceptance criteria: NMT 0.5%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Minoxidil RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MINOXIDIL	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(2)

Current DocID: GUID-5C8F4BBF-46C6-4822-BB7C-22D21F84A54A_4_en-US

DOI: https://doi.org/10.31003/USPNF_M54250_04_01

DOI ref: [0x0pp](#)